FDA Grants Fast-Track to Potential Heart Failure Drug

The FDA granted fast-track designation for an investigational heart failure treatment being developed by Amgen and Cytokinetics.

Omecamtiv mecarbil is currently in phase 3 testing for reducing the risk of cardiovascular death in patients with heart failure.

The novel investigational drug is designed to activate myosin, a protein in heart muscle that helps produce a heartbeat.